A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

A Randomized Phase II Study of Adebrelimab in Combination with Chemotherapy with or Without Bevacizumab Neoadjuvant Therapy for Resectable Non-Squamous Non-Small Cell Lung Cancer

This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.

Neoadjuvant therapy with experimental treatment followed by surgery.

Inclusion Criteria:

• Resectable NSQ NSCLC
• Age 18-65 years
• male or female
• ECOG 0-1
• Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer
• Subjects must have adequate pulmonary function for the intended pneumonectomy;

Exclusion Criteria:

• SCLC or SQ NSCLC
• previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc.
• patients who have previously used anti-angiogenic drugs;
• allergic to any component of the study drug or chemotherapy drugs
• patients with any severe and or uncontrolled disease